148 related articles for article (PubMed ID: 15165005)
1. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy.
Krassas GE
J Endocrinol Invest; 2004 Mar; 27(3):281-7. PubMed ID: 15165005
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogues in the treatment of thyroid eye disease.
Krassas GE
Thyroid; 1998 May; 8(5):443-5. PubMed ID: 9623741
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin therapy and Graves' ophthalmopathy.
Krassas G; Kaltsas T; Pontikides N; Dumas A
Thyroid; 1997 Jun; 7(3):489. PubMed ID: 9226222
[No Abstract] [Full Text] [Related]
4. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
6. The role of somatostatin analogs in the management of Graves' ophthalmopathy.
Bartalena L; Tanda ML; Piantanida E; Lai A
J Endocrinol Invest; 2003; 26(8 Suppl):109-13. PubMed ID: 15233224
[No Abstract] [Full Text] [Related]
7. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
Krassas GE
Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
[TBL] [Abstract][Full Text] [Related]
8. Graves' ophthalmopathy: state of the art and perspectives.
Bartalena L; Wiersinga WM; Pinchera A
J Endocrinol Invest; 2004 Mar; 27(3):295-301. PubMed ID: 15165007
[TBL] [Abstract][Full Text] [Related]
9. Perspectives of new potential therapeutic applications of somatostatin analogs.
Pawlikowski M; Melen-Mucha G
Neuro Endocrinol Lett; 2003; 24(1-2):21-7. PubMed ID: 12743527
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today.
Krassas GE; Gogakos A; Boboridis K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():204-9. PubMed ID: 20467364
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogs in medical treatment of acromegaly.
Racine MS; Barkan AL
Endocrine; 2003 Apr; 20(3):271-8. PubMed ID: 12721507
[TBL] [Abstract][Full Text] [Related]
12. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
Wémeau JL; Caron P; Beckers A; Rohmer V; Orgiazzi J; Borson-Chazot F; Nocaudie M; Perimenis P; Bisot-Locard S; Bourdeix I; Dejager S
J Clin Endocrinol Metab; 2005 Feb; 90(2):841-8. PubMed ID: 15562016
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogs for Graves' ophthalmopathy: do they bounce off like a rubber bullet?
Bartalena L; Marcocci C; Pinchera A
J Clin Endocrinol Metab; 2004 Dec; 89(12):5908-9. PubMed ID: 15579734
[No Abstract] [Full Text] [Related]
14. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
15. Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.
Marcocci C; Marinò M; Rocchi R; Menconi F; Morabito E; Pinchera A
J Endocrinol Invest; 2004 Mar; 27(3):272-80. PubMed ID: 15165004
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
17. [Lanreotide in the treatment of thyroid orbitopathy].
Pilarska K; Kulig G
Przegl Lek; 2004; 61(8):845-7. PubMed ID: 15789913
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogs for cancer treatment and diagnosis: an overview.
Scarpignato C; Pelosini I
Chemotherapy; 2001; 47 Suppl 2():1-29. PubMed ID: 11275699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
